| Market Cap | 1.22TCr 1.05TCr 987.2Cr 901.81Cr 1.69TCr 1,15100Cr 1.69TCr 12TCr 4.53TCr 59TCr 4.58TCr 4.48TCr 1,90300Cr | P/E 2026 * |
54.8x | P/E 2027 * | 26.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.22TCr 1.05TCr 987.2Cr 901.81Cr 1.69TCr 1,15100Cr 1.69TCr 12TCr 4.53TCr 59TCr 4.58TCr 4.48TCr 1,90300Cr | EV / Sales 2026 * |
10.6x | EV / Sales 2027 * | 7.15x |
| Free-Float |
65.9% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 01/01/1999 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 01/03/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 01/01/1999 |
James Wilson
CHM | Chairman | 82 | 01/01/1999 |
David Mahoney
BRD | Director/Board Member | 71 | 01/07/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 1.22TCr | |
| -1.15% | -2.47% | +54.20% | +105.23% | 1,03400Cr | |
| -0.73% | +3.15% | +54.67% | +72.07% | 67TCr | |
| -1.10% | +0.70% | +20.78% | +76.08% | 46TCr | |
| +0.14% | -0.47% | +29.49% | +38.56% | 35TCr | |
| -1.33% | +4.72% | +24.69% | +45.55% | 31TCr | |
| -1.15% | +0.30% | -1.49% | +12.31% | 26TCr | |
| -1.46% | +1.32% | +56.41% | +72.48% | 24TCr | |
| -0.88% | +1.15% | -17.09% | -54.39% | 21TCr | |
| -0.07% | +3.59% | +33.82% | +100.78% | 19TCr | |
| Average | -0.74% | +1.27% | +28.39% | +52.07% | 41.3TCr | |
| Weighted average by Cap. | -0.90% | +1.04% | +36.66% | +66.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 114.62Cr 99Cr 93Cr 85Cr 158.57Cr 11TCr 159.01Cr 1.1TCr 425.5Cr 5.55TCr 430.39Cr 421.01Cr 18TCr | 170.49Cr 146.71Cr 138.03Cr 126.09Cr 235.88Cr 16TCr 236.52Cr 1.63TCr 632.93Cr 8.26TCr 640.21Cr 626.24Cr 27TCr |
| Net income | 24Cr 21Cr 20Cr 18Cr 33Cr 2.28TCr 34Cr 231.08Cr 90Cr 1.17TCr 91Cr 89Cr 3.77TCr | 59Cr 51Cr 48Cr 44Cr 82Cr 5.6TCr 82Cr 567.91Cr 220.37Cr 2.88TCr 222.91Cr 218.05Cr 9.26TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
